Feb. 2 (Bloomberg) -- The following companies may have unusual price changes in Japanese trading today. Stock symbols are in parentheses, and share prices are as of the latest close. The information in each item was released after markets shut unless stated otherwise.
Mitsubishi UFJ Financial Group Inc. (8306 JT): Japan’s biggest bank by market value posted a 39 percent decline in third-quarter profit as lending income fell. The bank maintained its 900 billion yen ($11.8 billion) profit target for the year ending March 31. The stock added 2.9 percent to 359 yen.
Nomura Holdings Inc. (8604 JT): Japan’s biggest brokerage by market value said quarterly profit unexpectedly rose 33 percent as gains from selling private-equity investments outweighed a plunge in trading and commissions as well as widening losses overseas. The stock rose 0.4 percent to 280 yen.
Sharp Corp. (6753 JT): The maker of Aquos televisions forecast its worst annual loss since it was founded in 1912, citing slumping prices for liquid-crystal-display TVs and a tax write-off. The loss may be 290 billion yen for the year ending March 31, the Osaka-based company said in a statement. Sharp slid 4.3 percent to 628 yen.
Sony Corp. (6758 JT): Japan’s No. 1 exporter of consumer electronics replaced Howard Stringer, naming Kazuo Hirai president and chief executive officer, after forecasting a fourth consecutive year of losses. The management change is effective April 1. The stock dropped 1.9 percent to 1,364 yen.
Sumco Corp. (3436 JT): The maker of silicon wafers for semiconductors will close two domestic plants and cut about 1,000 jobs as demand for chips used in televisions and computers has dropped, the Nikkei newspaper reported without citing anyone. The company will book an extraordinary loss of about 100 billion yen charge and is considering boosting its capital by about 50 billion yen, the report said. The company will also exit its solar silicon wafer business, the newspaper said. The stock rose 3.4 percent to 675 yen.
Takeda Pharmaceutical Co. (4502 JT): Asia’s biggest drugmaker forecast a fiscal fourth-quarter loss on restructuring costs related to the 9.6 billion euro ($13 billion) takeover of Swiss-based Nycomed in September. Takeda said it will record a loss of 30.6 billion yen in the three months ending March 31, compared with net income of 32.4 billion yen a year earlier. The stock fell 0.5 percent to 3,295 yen.
To contact the reporter on this story: Yoshiaki Nohara in Tokyo at email@example.com
To contact the editor responsible for this story: Nick Gentle at firstname.lastname@example.org